Podcast Episodes
Back to Search
Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week for its first-in-class orexin agonist for treating narcolepsy type 1
Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two positive phase …
1 year ago
Leaders of Brandon Capital, a seed and VC firm formed in Australia and with an office in the UK as well, discuss their $290 million sixth fund
Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running speedy clinica…
1 year ago
Biotech veteran Harvey Berger was named Chairman & CEO of Arena BioWorks today - he describes how 'foraging to focusing' will be the name of the game
Dr. Berger, whose experience in biotech goes back decades, including founding and running ARIAD for 25 years, is taking over this company that was pu…
1 year ago
Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS
CEO Neil Miller walks us through the hypothesis of how toxic proteins created by neurodegenerative diseases enter and damage the mitochondria, and ho…
1 year ago
Fairtility has received FDA clearance on its AI-based embryo assessment tool for IVF, CHLOE Blast, that helps embryologists with embryo and oocyte assessments
Co-Founder and CEO Eran Eshed describes the unmet need and how CHLOE Blast analyzes images from a time-laps incubator.
1 year ago
N-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works
He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and resources to run f…
1 year ago
Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
He shares what he believes the takeaways are from MAPLE-HCM, which studied aficamten vs a beta blocker in symptomatic obstructive hypertrophic cardio…
1 year ago
John Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans
Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for atherosclerotic cardiovasc…
1 year ago
The CEO of Tennr, which raised a $101M series C earlier this summer, explains how the company's platform uses large language models to make the patient referral process to specialists more efficient
Trey Holterman describes how Tennr is trying to fix this process which relies on significant unstructured data and has traditional leads to onerous d…
1 year ago
Stanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant
Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate internally …
1 year ago